Remove 2030 Remove Negotiation Remove Valuation
article thumbnail

Exit Planning Through an Investment Banker’s Lens

Focus Investment Banking

If your goal is full retirement by 2030, plan to sell by 2028 or 2029. This target is negotiated and agreed upon, and the investment banking advisor will play a large role here. These are called addbacks, and are extremely important to valuation. Heres a step-by-step planning guide, starting with what to tackle first: 1.

article thumbnail

Ready to Sell Your HVAC Business?

Sun Acquisitions

billion valuation by 2030. The first step in positioning your HVAC business for a favorable acquisition is increasing its current valuation. Once you’ve done this, you can move on to the next step – organizing your books in preparation for business valuation. Step #2 Organize Your Books and Get a Business Valuation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Venture Capital Interview Questions: What to Expect and How to Prepare

Mergers and Inquisitions

Technical Questions – You could get standard questions about accounting and valuation or VC-specific questions about cap tables, key metrics in your industry, or how to value startups. If you worked at a startup, how did you win more customers or partners in a sales or business development role? Q: Which current startup would you invest in?

Capital 59
article thumbnail

Education Software in Today’s Schools: Sector Trends and M&A Insights

Software Equity Group

billion by 2030. K-12 Education Software The K-12 market comprises more than 13,000 school districts, nearly 130,000 public schools, 3-4 million teachers, and 47 million students. In 2022, the higher-ed tech market was estimated to be about $36.2 billion and is projected to grow to $42.7

article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

By 2030, more than 190 commercial drugs will lose patent exclusivity , putting at risk $236 billion in Big Pharma sales. 2024 saw companies focusing on internal research and development, innovative partnerships, and targeted bolt-on asset acquisitions to bolster their pipelines.

M&A 64